ACADIA Pharmaceuticals Inc. (ACAD)
USD 14.59
(3.4%)
USD 14.59
(3.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 317.2 Million USD | 69.27% |
| 2022 | 187.39 Million USD | 17.69% |
| 2021 | 159.22 Million USD | 2.33% |
| 2020 | 155.6 Million USD | 85.14% |
| 2019 | 84.04 Million USD | 37.51% |
| 2018 | 61.12 Million USD | 24.18% |
| 2017 | 49.22 Million USD | 15.16% |
| 2016 | 42.74 Million USD | 93.11% |
| 2015 | 22.13 Million USD | 38.61% |
| 2014 | 15.96 Million USD | 128.55% |
| 2013 | 6.98 Million USD | -70.4% |
| 2012 | 23.6 Million USD | 169.72% |
| 2011 | 8.75 Million USD | 0.53% |
| 2010 | 8.7 Million USD | -76.82% |
| 2009 | 37.56 Million USD | 221.49% |
| 2008 | 11.68 Million USD | -43.41% |
| 2007 | 20.65 Million USD | -7.75% |
| 2006 | 22.38 Million USD | -3.24% |
| 2005 | 23.13 Million USD | 138.88% |
| 2004 | 9.68 Million USD | -88.52% |
| 2003 | 84.36 Million USD | 50.35% |
| 2002 | 56.11 Million USD | 1269.62% |
| 2001 | 4.09 Million USD | -92.76% |
| 2000 | 56.62 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 397.39 Million USD | 1.62% |
| 2024 Q1 | 391.05 Million USD | 23.28% |
| 2023 Q1 | 281.04 Million USD | 49.97% |
| 2023 Q4 | 317.2 Million USD | 17.32% |
| 2023 Q3 | 270.36 Million USD | 9.47% |
| 2023 FY | 317.2 Million USD | 69.27% |
| 2023 Q2 | 246.97 Million USD | -12.12% |
| 2022 Q2 | 177.91 Million USD | -0.86% |
| 2022 Q1 | 179.45 Million USD | 12.7% |
| 2022 FY | 187.39 Million USD | 17.69% |
| 2022 Q4 | 187.39 Million USD | 5.99% |
| 2022 Q3 | 176.8 Million USD | -0.63% |
| 2021 Q4 | 159.22 Million USD | 5.65% |
| 2021 Q1 | 173.56 Million USD | 11.54% |
| 2021 FY | 159.22 Million USD | 2.33% |
| 2021 Q2 | 159.59 Million USD | -8.05% |
| 2021 Q3 | 150.71 Million USD | -5.56% |
| 2020 Q4 | 155.6 Million USD | 10.52% |
| 2020 FY | 155.6 Million USD | 85.14% |
| 2020 Q1 | 109.06 Million USD | 29.77% |
| 2020 Q2 | 96.63 Million USD | -11.4% |
| 2020 Q3 | 140.79 Million USD | 45.7% |
| 2019 Q4 | 84.04 Million USD | 10.16% |
| 2019 Q2 | 71.96 Million USD | -13.03% |
| 2019 FY | 84.04 Million USD | 37.51% |
| 2019 Q3 | 76.29 Million USD | 6.01% |
| 2019 Q1 | 82.74 Million USD | 35.38% |
| 2018 FY | 61.12 Million USD | 24.18% |
| 2018 Q1 | 46.87 Million USD | -4.77% |
| 2018 Q2 | 50.24 Million USD | 7.19% |
| 2018 Q3 | 43.01 Million USD | -14.38% |
| 2018 Q4 | 61.12 Million USD | 42.09% |
| 2017 Q1 | 45.48 Million USD | 6.43% |
| 2017 Q2 | 41.17 Million USD | -9.48% |
| 2017 Q4 | 49.22 Million USD | 35.27% |
| 2017 FY | 49.22 Million USD | 15.16% |
| 2017 Q3 | 36.38 Million USD | -11.63% |
| 2016 Q3 | 39.32 Million USD | 34.59% |
| 2016 Q4 | 42.74 Million USD | 8.69% |
| 2016 Q2 | 29.21 Million USD | 36.93% |
| 2016 Q1 | 21.33 Million USD | -3.59% |
| 2016 FY | 42.74 Million USD | 93.11% |
| 2015 Q2 | 19.71 Million USD | 16.89% |
| 2015 Q3 | 17.97 Million USD | -8.84% |
| 2015 Q1 | 16.86 Million USD | 5.64% |
| 2015 Q4 | 22.13 Million USD | 23.14% |
| 2015 FY | 22.13 Million USD | 38.61% |
| 2014 Q3 | 11.27 Million USD | 20.49% |
| 2014 Q2 | 9.35 Million USD | 16.29% |
| 2014 Q4 | 15.96 Million USD | 41.64% |
| 2014 Q1 | 8.04 Million USD | 15.16% |
| 2014 FY | 15.96 Million USD | 128.55% |
| 2013 FY | 6.98 Million USD | -70.4% |
| 2013 Q1 | 23.35 Million USD | -1.07% |
| 2013 Q4 | 6.98 Million USD | -62.3% |
| 2013 Q3 | 18.53 Million USD | -27.14% |
| 2013 Q2 | 25.43 Million USD | 8.91% |
| 2012 FY | 23.6 Million USD | 169.72% |
| 2012 Q4 | 23.6 Million USD | 287.87% |
| 2012 Q3 | 6.08 Million USD | -33.6% |
| 2012 Q2 | 9.16 Million USD | 2.6% |
| 2012 Q1 | 8.93 Million USD | 2.08% |
| 2011 FY | 8.75 Million USD | 0.53% |
| 2011 Q4 | 8.75 Million USD | -1.42% |
| 2011 Q1 | 8.77 Million USD | 0.84% |
| 2011 Q2 | 8.48 Million USD | -3.31% |
| 2011 Q3 | 8.87 Million USD | 4.59% |
| 2010 Q3 | 35.92 Million USD | -0.24% |
| 2010 Q2 | 36.01 Million USD | -0.46% |
| 2010 FY | 8.7 Million USD | -76.82% |
| 2010 Q4 | 8.7 Million USD | -75.77% |
| 2010 Q1 | 36.17 Million USD | -3.7% |
| 2009 Q3 | 39.5 Million USD | -9.49% |
| 2009 Q2 | 43.65 Million USD | 264.21% |
| 2009 FY | 37.56 Million USD | 221.49% |
| 2009 Q1 | 11.98 Million USD | 2.57% |
| 2009 Q4 | 37.56 Million USD | -4.92% |
| 2008 Q3 | 11.96 Million USD | -19.6% |
| 2008 Q4 | 11.68 Million USD | -2.31% |
| 2008 FY | 11.68 Million USD | -43.41% |
| 2008 Q1 | 14.65 Million USD | -29.02% |
| 2008 Q2 | 14.87 Million USD | 1.49% |
| 2007 Q2 | 15.95 Million USD | -15.84% |
| 2007 Q4 | 20.65 Million USD | 10.95% |
| 2007 Q3 | 18.61 Million USD | 16.68% |
| 2007 Q1 | 18.95 Million USD | -15.33% |
| 2007 FY | 20.65 Million USD | -7.75% |
| 2006 Q2 | 27.02 Million USD | 14.21% |
| 2006 Q3 | 22.51 Million USD | -16.69% |
| 2006 Q4 | 22.38 Million USD | -0.57% |
| 2006 FY | 22.38 Million USD | -3.24% |
| 2006 Q1 | 23.65 Million USD | 2.27% |
| 2005 Q4 | 23.13 Million USD | 9.78% |
| 2005 FY | 23.13 Million USD | 138.88% |
| 2005 Q1 | 13.55 Million USD | 39.95% |
| 2005 Q2 | 12.48 Million USD | -7.91% |
| 2005 Q3 | 21.07 Million USD | 68.85% |
| 2004 Q3 | 10.39 Million USD | -1.15% |
| 2004 Q4 | 9.68 Million USD | -6.79% |
| 2004 Q1 | 85.83 Million USD | 1.74% |
| 2004 FY | 9.68 Million USD | -88.52% |
| 2004 Q2 | 10.51 Million USD | -87.75% |
| 2003 Q4 | 84.36 Million USD | 0.0% |
| 2003 FY | 84.36 Million USD | 50.35% |
| 2002 FY | 56.11 Million USD | 1269.62% |
| 2001 FY | 4.09 Million USD | -92.76% |
| 2000 FY | 56.62 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 72.56 Million USD | -337.115% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -8889.111% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -16116.82% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -726.625% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 34.813% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -143.37% |
| Agenus Inc. | 462.29 Million USD | 31.386% |
| Fortress Biotech, Inc. | 165.93 Million USD | -91.155% |
| GlycoMimetics, Inc. | 6.9 Million USD | -4495.735% |
| Novavax, Inc. | 2.57 Billion USD | 87.668% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -738.89% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1850.446% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -565.689% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -39.84% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -16.495% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 92.169% |
| AlloVir, Inc. | 45.01 Million USD | -604.656% |
| Aptorum Group Limited | 5.25 Million USD | -5934.179% |
| Ardelyx, Inc. | 130.76 Million USD | -142.577% |
| Bicycle Therapeutics plc | 224.41 Million USD | -41.348% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -143.607% |
| Chimerix, Inc. | 19.74 Million USD | -1506.488% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -801.725% |
| CRISPR Therapeutics AG | 346.76 Million USD | 8.526% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -535.291% |
| Precision BioSciences, Inc. | 140.92 Million USD | -125.093% |
| Dyadic International, Inc. | 2.34 Million USD | -13451.828% |
| Elevation Oncology, Inc. | 34.28 Million USD | -825.27% |
| Fortress Biotech, Inc. | 165.93 Million USD | -91.155% |
| GT Biopharma, Inc. | 6.63 Million USD | -4682.165% |
| Alkermes plc | 933.53 Million USD | 66.022% |
| Immix Biopharma, Inc. | 3.72 Million USD | -8422.824% |
| Innoviva, Inc. | 568.55 Million USD | 44.209% |
| IO Biotech, Inc. | 17.55 Million USD | -1706.795% |
| Jaguar Health, Inc. | 45.86 Million USD | -591.582% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -142.681% |
| ContextLogic Inc. | 206 Million USD | -53.981% |
| AbCellera Biologics Inc. | 335.77 Million USD | 5.532% |
| Lantern Pharma Inc. | 2.73 Million USD | -11478.023% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -12873.456% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 33.694% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -34.856% |
| MEI Pharma, Inc. | 8.35 Million USD | -3696.541% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -1052.997% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -4700.781% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -105.784% |
| NextCure, Inc. | 14.99 Million USD | -2015.096% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -343.762% |
| ChromaDex Corporation | 26.5 Million USD | -1096.624% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -1023.79% |
| Incyte Corporation | 1.59 Billion USD | 80.079% |
| Opthea Limited | 264.6 Million USD | -19.879% |
| MiMedx Group, Inc. | 96.33 Million USD | -229.286% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -578.664% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -1064.981% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -2520.478% |
| Vaxcyte, Inc. | 167.44 Million USD | -89.431% |
| PDS Biotechnology Corporation | 33.25 Million USD | -853.726% |
| Pharming Group N.V. | 244.07 Million USD | -29.962% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -2560.636% |
| Onconetix, Inc. | 23.18 Million USD | -1268.373% |
| Acelyrin, Inc. | 86.35 Million USD | -267.331% |
| PureTech Health plc | 125.58 Million USD | -152.583% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -560.533% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -148.219% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -8888.698% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -4700.781% |
| ESSA Pharma Inc. | 3.49 Million USD | -8975.667% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -117.456% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -7747.625% |
| Seer, Inc. | 39.36 Million USD | -705.794% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -284.799% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -2106.002% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -4674.966% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -24314.331% |
| Summit Therapeutics Inc. | 125.25 Million USD | -153.24% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -3246.355% |
| Senti Biosciences, Inc. | 52.57 Million USD | -503.376% |
| ImmuCell Corporation | 18.81 Million USD | -1585.892% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -109.357% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -779.697% |
| Precigen, Inc. | 41.64 Million USD | -661.697% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -3145.355% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -4650.651% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -361.202% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 8.74% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -23650.341% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 35.855% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -412.988% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -3286.367% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -3444.145% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -993.231% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -39.463% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -130.189% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -2806.368% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -19.975% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -277.503% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -1067.511% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -9733.333% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -330.004% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1906.496% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2773.279% |
| Soligenix, Inc. | 7.27 Million USD | -4260.209% |
| Century Therapeutics, Inc. | 175.94 Million USD | -80.288% |
| Kura Oncology, Inc. | 51.66 Million USD | -513.993% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -161.54% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -7574.837% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -4696.008% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -25.575% |
| Autolus Therapeutics plc | 263.9 Million USD | -20.194% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2926.15% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -256.963% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -576.349% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 10.105% |
| GRI Bio, Inc. | 2.69 Million USD | -11661.253% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -39080.691% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -920.234% |
| IGM Biosciences, Inc. | 220.17 Million USD | -44.066% |
| INmune Bio, Inc. | 18.86 Million USD | -1581.693% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -23.675% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -1090.613% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -11568.64% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -9569.978% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -442.641% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -229.871% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -19.818% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 61.459% |
| Verastem, Inc. | 71.18 Million USD | -345.601% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -545.032% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -722.233% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -548.249% |
| Histogen Inc. | 5.69 Million USD | -5467.86% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -7132.776% |
| Surrozen, Inc. | 8.14 Million USD | -3794.426% |
| Organovo Holdings, Inc. | 2.74 Million USD | -11442.977% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -100965.131% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -464.115% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -1821.033% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -520.709% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -38261.421% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -150.307% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2833.355% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -110.221% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -12065.67% |
| Apollomics, Inc. | 14.15 Million USD | -2141.228% |
| Amarin Corporation plc | 279.58 Million USD | -13.453% |
| Mesoblast Limited | 188.79 Million USD | -68.011% |
| Turnstone Biologics Corp. | 14.14 Million USD | -2142.02% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -75.455% |
| Synaptogenix, Inc. | 5.52 Million USD | -5636.554% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -4671.375% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -86.47% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -3606.835% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -17949.52% |
| Exelixis, Inc. | 678.44 Million USD | 53.246% |
| Better Therapeutics, Inc. | 23.84 Million USD | -1230.429% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -93.361% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 46.618% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2869.99% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -19436.701% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -714.861% |
| Gritstone bio, Inc. | 125.91 Million USD | -151.909% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -2061.359% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -6133.528% |
| Avid Bioservices, Inc. | 275.66 Million USD | -15.066% |
| Insmed Incorporated | 1.66 Billion USD | 80.912% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -4022.693% |
| MediWound Ltd. | 27.18 Million USD | -1066.738% |
| OmniAb, Inc. | 87.4 Million USD | -262.93% |
| Alector, Inc. | 487.66 Million USD | 34.956% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 21.379% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1621.579% |
| Zai Lab Limited | 240.17 Million USD | -32.07% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 49.655% |
| Aura Biosciences, Inc. | 29.22 Million USD | -985.301% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -233.625% |
| Immunic, Inc. | 25.36 Million USD | -1150.398% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -358.145% |
| Veracyte, Inc. | 93.71 Million USD | -238.46% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -12022.302% |
| FibroGen, Inc. | 585.72 Million USD | 45.845% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1724.777% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -48470.304% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -5508.759% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 95.857% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -3769.249% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -277.521% |
| TG Therapeutics, Inc. | 169.08 Million USD | -87.599% |
| Galecto, Inc. | 5.89 Million USD | -5279.936% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -3729.08% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 87.886% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -1000.552% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -2413.279% |
| XBiotech Inc. | 8.39 Million USD | -3677.552% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -2061.359% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -496.467% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 12.642% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -1079.888% |
| Theravance Biopharma, Inc. | 169 Million USD | -87.688% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 73.906% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 36.614% |
| Vaxxinity, Inc. | 30.94 Million USD | -925.081% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 67.383% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -5159.416% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 57.436% |
| NexImmune, Inc. | 5.08 Million USD | -6138.917% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -85308.219% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -10215.99% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 95.537% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -6054.427% |
| Scopus BioPharma Inc. | 7.45 Million USD | -4155.199% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -1106.363% |
| Ainos, Inc. | 7.39 Million USD | -4189.849% |
| Pluri Inc. | 34.11 Million USD | -829.881% |
| Prothena Corporation plc | 135.01 Million USD | -134.934% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -30.48% |
| Celularity Inc. | 102.92 Million USD | -208.175% |
| Rallybio Corporation | 9.43 Million USD | -3261.604% |
| Cue Biopharma, Inc. | 24.44 Million USD | -1197.611% |
| MeiraGTx Holdings plc | 319.99 Million USD | 0.872% |
| Omeros Corporation | 403.25 Million USD | 21.339% |
| Humacyte, Inc. | 114.67 Million USD | -176.604% |
| Immunocore Holdings plc | 228.15 Million USD | -39.027% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -6406.687% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -313.345% |
| Blueprint Medicines Corporation | 918.64 Million USD | 65.471% |
| CalciMedica, Inc. | 4.02 Million USD | -7774.901% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1717.562% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -269.625% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -14.186% |
| Pulmatrix, Inc. | 15.96 Million USD | -1887.101% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1911.038% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -1189.121% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -26.472% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -524.583% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 73.799% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -898.021% |
| Nutriband Inc. | 1.07 Million USD | -29299.89% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2883.175% |
| Vor Biopharma Inc. | 59.1 Million USD | -436.683% |
| Roivant Sciences Ltd. | 773.95 Million USD | 59.015% |
| Evogene Ltd. | 17.99 Million USD | -1663.207% |
| ProKidney Corp. | 29.21 Million USD | -985.71% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -340.685% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -44894.135% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 83.207% |
| CorMedix Inc. | 11.91 Million USD | -2561.634% |
| BioLineRx Ltd. | 50.7 Million USD | -525.618% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -112.233% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -258.658% |
| Atai Life Sciences N.V. | 49.16 Million USD | -545.216% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -918.226% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1665.956% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -154.502% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -5510.205% |
| MediciNova, Inc. | 3.89 Million USD | -8051.013% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1635.33% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -20987.113% |
| GeoVax Labs, Inc. | 3.51 Million USD | -8911.697% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 20.153% |
| Biomea Fusion, Inc. | 30.69 Million USD | -933.565% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 88.346% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1887.226% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -916.637% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -440.524% |
| Absci Corporation | 58.3 Million USD | -444.047% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1565.272% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -889.336% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -329.87% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -262.586% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -839.298% |
| Allakos Inc. | 74.79 Million USD | -324.105% |
| Imunon, Inc. | 8.53 Million USD | -3618.466% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -1309.72% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -176.279% |
| BioAtla, Inc. | 48.98 Million USD | -547.534% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2869.99% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -11314.214% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -142.872% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -2131.453% |
| XOMA Corporation | 145.58 Million USD | -117.888% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -842.228% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -361.323% |
| aTyr Pharma, Inc. | 31.59 Million USD | -903.896% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -413.079% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -605.44% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -555.347% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -10952.3% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -3788.212% |
| Akari Therapeutics, Plc | 4.58 Million USD | -6819.743% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1688.748% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 80.769% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -78432.983% |
| UroGen Pharma Ltd. | 243.52 Million USD | -30.255% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 1.21% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -11386.306% |
| Orgenesis Inc. | 35.53 Million USD | -792.644% |
| Entera Bio Ltd. | 1.37 Million USD | -22902.248% |
| GH Research PLC | 6.7 Million USD | -4633.637% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -4564.721% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1584.909% |
| Xencor, Inc. | 283.55 Million USD | -11.864% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -10524.097% |
| Replimune Group, Inc. | 113.21 Million USD | -180.178% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -8342.652% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -206.386% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -78432.983% |
| Portage Biotech Inc. | 4.45 Million USD | -7028.112% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -20987.113% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -1276.143% |
| OncoCyte Corporation | 49.29 Million USD | -543.436% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -7567.777% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -39675.218% |
| Purple Biotech Ltd. | 10 Million USD | -3070.425% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -5382.216% |
| scPharmaceuticals Inc. | 57.26 Million USD | -453.956% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -2460.546% |
| HilleVax, Inc. | 78.9 Million USD | -301.983% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -6181.208% |
| Tharimmune, Inc. | 1.81 Million USD | -17376.196% |
| Genprex, Inc. | 3.25 Million USD | -9647.41% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -1069.663% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -5958.079% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -153881.068% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -88368.211% |
| OKYO Pharma Limited | 7.42 Million USD | -4174.459% |
| Savara Inc. | 37.19 Million USD | -752.874% |
| Curis, Inc. | 57.61 Million USD | -450.581% |
| Daré Bioscience, Inc. | 26.32 Million USD | -1104.72% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -709.19% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -21866.828% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1423.613% |
| BeiGene, Ltd. | 2.23 Billion USD | 85.8% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -1389.92% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -20.886% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1391.027% |
| Erasca, Inc. | 78.61 Million USD | -303.507% |
| bluebird bio, Inc. | 424.62 Million USD | 25.298% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -48309.009% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 83.217% |
| DBV Technologies S.A. | 42.8 Million USD | -641.124% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -48309.009% |
| Moderna, Inc. | 4.57 Billion USD | 93.062% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -4434.682% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -19054.65% |
| Molecular Templates, Inc. | 31.17 Million USD | -917.616% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1758.237% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 46.064% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -154.77% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -1056.107% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -770.093% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -470.146% |
| MacroGenics, Inc. | 154.2 Million USD | -105.698% |
| RenovoRx, Inc. | 4.46 Million USD | -7002.575% |
| Adicet Bio, Inc. | 37.12 Million USD | -754.529% |
| Prime Medicine, Inc. | 60.78 Million USD | -421.884% |
| Aditxt, Inc. | 28.53 Million USD | -1011.755% |
| Adagene Inc. | 45.16 Million USD | -602.248% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -175439.15% |
| Quantum-Si incorporated | 26.63 Million USD | -1091.097% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 54.527% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -10325.882% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -175.921% |
| SciSparc Ltd. | 1.59 Million USD | -19787.21% |
| Vericel Corporation | 127.7 Million USD | -148.386% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -5600.037% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -271.612% |
| Generation Bio Co. | 171.63 Million USD | -84.817% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -2646.329% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -658.292% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -25.526% |
| Invivyd, Inc. | 51.71 Million USD | -513.387% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -244.87% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -4776.076% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -320.156% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -30967.679% |
| 2seventy bio, Inc. | 310.12 Million USD | -2.281% |
| ADMA Biologics, Inc. | 193.97 Million USD | -63.526% |
| Clene Inc. | 38.95 Million USD | -714.359% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -777.874% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -23.436% |
| GeoVax Labs, Inc. | 3.51 Million USD | -8911.697% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -66.717% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -2504.35% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -59.942% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -2501.117% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -559.311% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -500.293% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 14.236% |
| Evaxion Biotech A/S | 17.61 Million USD | -1700.49% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -97.106% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -107.069% |
| Trevena, Inc. | 48.26 Million USD | -557.248% |
| Surrozen, Inc. | 8.14 Million USD | -3794.426% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1368.863% |
| Cingulate Inc. | 10.36 Million USD | -2961.53% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -11434.582% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -750.587% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -8744.256% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -2312.175% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -1176.514% |
| Clearmind Medicine Inc. | 3.61 Million USD | -8686.712% |
| Kronos Bio, Inc. | 54.2 Million USD | -485.231% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -574.279% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1293.694% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1480.395% |
| Statera Biopharma, Inc. | 22.67 Million USD | -1298.812% |
| ImmunityBio, Inc. | 1.09 Billion USD | 70.909% |
| Korro Bio, Inc. | 51.75 Million USD | -512.925% |
| Kineta, Inc. | 7.22 Million USD | -4292.149% |
| BioVie Inc. | 9.7 Million USD | -3169.395% |
| Codexis, Inc. | 49.94 Million USD | -535.088% |
| Celularity Inc. | 102.92 Million USD | -208.175% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -229.57% |
| Celcuity Inc. | 51.45 Million USD | -516.522% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -91790.647% |
| Cibus, Inc. | 206.11 Million USD | -53.894% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -646.795% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -1104.302% |
| IN8bio, Inc. | 8.77 Million USD | -3516.062% |
| Kodiak Sciences Inc. | 213.59 Million USD | -48.509% |
| Annexon, Inc. | 47.11 Million USD | -573.206% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -254.252% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -229.142% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -2217.196% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 87.816% |
| Eyenovia, Inc. | 19.78 Million USD | -1503.622% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -79.123% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -4029.684% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -1216.241% |
| Arcellx, Inc. | 339.75 Million USD | 6.637% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -2566.003% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -29.185% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -3216.961% |
| Moolec Science SA | 13.94 Million USD | -2174.6% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -635.078% |
| Geron Corporation | 146.12 Million USD | -117.072% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -527.723% |
| Royalty Pharma plc | 6.29 Billion USD | 94.963% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -697.468% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -107642.709% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -12792.872% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -67.693% |
| Humacyte, Inc. | 114.67 Million USD | -176.604% |
| Structure Therapeutics Inc. | 29.05 Million USD | -991.876% |
| 89bio, Inc. | 59.96 Million USD | -428.995% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -1098.659% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -26421.823% |
| Genelux Corporation | 8.42 Million USD | -3667.233% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -4526.619% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -132.69% |
| Notable Labs, Ltd. | 4.42 Million USD | -7065.146% |
| Liquidia Corporation | 73.13 Million USD | -333.702% |
| Mustang Bio, Inc. | 17.61 Million USD | -1700.335% |
| Immunovant, Inc. | 48.95 Million USD | -547.944% |
| Quantum-Si incorporated | 26.63 Million USD | -1091.097% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -726.41% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -10122.398% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -329.457% |
| Acasti Pharma Inc. | 11.55 Million USD | -2644.666% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -1303.064% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -11568.64% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -760.159% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -23174.965% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -5103.428% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -1177.234% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -1268.189% |
| PepGen Inc. | 34.63 Million USD | -815.945% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -2511.998% |
| United Therapeutics Corporation | 1.18 Billion USD | 73.169% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -4441.824% |
| Solid Biosciences Inc. | 38.45 Million USD | -724.798% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -3606.835% |
| Immuneering Corporation | 12 Million USD | -2541.503% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -100965.131% |
| Silo Pharma, Inc. | 1.56 Million USD | -20113.284% |
| Belite Bio, Inc | 4.21 Million USD | -7432.676% |
| XOMA Corporation | 145.58 Million USD | -117.888% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -12964.292% |
| Bionomics Limited | 10.15 Million USD | -3022.45% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1375.971% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1284.371% |
| uniQure N.V. | 624.01 Million USD | 49.168% |
| Cassava Sciences, Inc. | 14.19 Million USD | -2134.597% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -175439.15% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -86.387% |
| Forte Biosciences, Inc. | 3.66 Million USD | -8552.51% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -121627.434% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -4601.364% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -4029.684% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1724.777% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2901.523% |
| Altimmune, Inc. | 16.54 Million USD | -1817.665% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 48.649% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1284.371% |
| Compugen Ltd. | 55.77 Million USD | -468.715% |
| Peak Bio, Inc. | 20.75 Million USD | -1428.432% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -187.156% |
| Benitec Biopharma Inc. | 4.96 Million USD | -6292.604% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -100.96% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -321.956% |
| Zura Bio Limited | 21.29 Million USD | -1389.766% |
| PolyPid Ltd. | 17.46 Million USD | -1715.898% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -182.21% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -321.956% |
| Instil Bio, Inc. | 99.8 Million USD | -217.833% |
| argenx SE | 444.95 Million USD | 28.711% |
| Immunome, Inc. | 28.65 Million USD | -1006.85% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -3704.738% |
| Verona Pharma plc | 58.84 Million USD | -439.082% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -2091.674% |
| Shattuck Labs, Inc. | 14.85 Million USD | -2034.74% |
| CervoMed Inc. | 2.59 Million USD | -12120.028% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -6408.022% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -2390.586% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2910.925% |
| Moolec Science SA | 13.94 Million USD | -2174.6% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -13435.33% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -470.554% |
| AnaptysBio, Inc. | 364.28 Million USD | 12.925% |
| Design Therapeutics, Inc. | 11.95 Million USD | -2553.07% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -2400.796% |
| NeurAxis, Inc. | 1.91 Million USD | -16483.601% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -714.84% |
| Lumos Pharma, Inc. | 13.33 Million USD | -2279.067% |
| Achilles Therapeutics plc | 19.08 Million USD | -1561.869% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -2091.674% |
| 180 Life Sciences Corp. | 5.38 Million USD | -5788.04% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -1244.756% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1293.694% |
| Nutriband Inc. | 1.07 Million USD | -29299.89% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -936.672% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -2085.935% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 20.952% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -876.815% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -2330.827% |
| Palisade Bio, Inc. | 2.73 Million USD | -11480.905% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -5938.473% |
| Beam Therapeutics Inc. | 478.38 Million USD | 33.693% |
| Neurogene Inc. | 36.54 Million USD | -767.879% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 20.291% |
| AEON Biopharma, Inc. | 159.88 Million USD | -98.388% |
| Sesen Bio, Inc. | 30.98 Million USD | -923.757% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -1121.837% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -4072.481% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -62.054% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -65.16% |
| Athira Pharma, Inc. | 30.05 Million USD | -955.332% |
| Vaccinex, Inc. | 5.94 Million USD | -5238.287% |
| HCW Biologics Inc. | 15.05 Million USD | -2007.376% |
| XOMA Corporation | 145.58 Million USD | -117.888% |
| Nektar Therapeutics | 267.04 Million USD | -18.781% |
| Arvinas, Inc. | 644.6 Million USD | 50.791% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1688.748% |
| Merus N.V. | 102.15 Million USD | -210.522% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -116.741% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -233.475% |
| Rezolute, Inc. | 11.73 Million USD | -2603.264% |
| Clene Inc. | 38.95 Million USD | -714.359% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -11040.101% |
| BeyondSpring Inc. | 48.26 Million USD | -557.153% |
| Synlogic, Inc. | 32.89 Million USD | -864.283% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -2070.677% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -19312.546% |
| Peak Bio, Inc. | 20.75 Million USD | -1428.432% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -399.852% |
| Krystal Biotech, Inc. | 39.71 Million USD | -698.713% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 15.782% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -218.574% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -73202.968% |
| MannKind Corporation | 721.36 Million USD | 56.028% |
| Ikena Oncology, Inc. | 22.33 Million USD | -1320.197% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -15106.184% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -209.193% |
| Gossamer Bio, Inc. | 249.14 Million USD | -27.315% |
| CohBar, Inc. | 1.03 Million USD | -30587.823% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2867.546% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1565.272% |
| Legend Biotech Corporation | 589.93 Million USD | 46.231% |
| Mural Oncology plc | 37.92 Million USD | -736.324% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -139.152% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -13719.395% |
| Disc Medicine, Inc. | 22.87 Million USD | -1286.671% |
| Champions Oncology, Inc. | 28.03 Million USD | -1031.446% |
| REGENXBIO Inc. | 262.22 Million USD | -20.964% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -9342.327% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2430.724% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -2261.598% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1395.878% |
| Vaxart, Inc. | 34.02 Million USD | -832.259% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1455.726% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -1011.742% |
| Cellectis S.A. | 249.57 Million USD | -27.096% |
| Longeveron Inc. | 5.33 Million USD | -5843.433% |
| Repare Therapeutics Inc. | 41.81 Million USD | -658.509% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 86.812% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -425.446% |
| Revolution Medicines, Inc. | 262.39 Million USD | -20.886% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -14954.627% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -3577.266% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -2587.916% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -2158.784% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -14646.676% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 93.841% |
| Denali Therapeutics Inc. | 122.96 Million USD | -157.965% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -5600.037% |
| Veru Inc. | 32.81 Million USD | -866.702% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -4517.863% |
| Cingulate Inc. | 10.36 Million USD | -2961.53% |
| Passage Bio, Inc. | 39.26 Million USD | -707.908% |
| Context Therapeutics Inc. | 4.19 Million USD | -7467.332% |
| Exicure, Inc. | 8.54 Million USD | -3610.387% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -974.966% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2924.995% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1339.141% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -94.619% |
| Nuvalent, Inc. | 31.82 Million USD | -896.766% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -4886.162% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -403.318% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1662.228% |
| OmniAb, Inc. | 87.4 Million USD | -262.93% |
| Anew Medical, Inc. | 8.24 Million USD | -3748.686% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -728.437% |
| Lipocine Inc. | 2.63 Million USD | -11953.409% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -1107.373% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -688.822% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -1090.613% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -268.179% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -5773.005% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -283.338% |
| Ocugen, Inc. | 23.98 Million USD | -1222.608% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -583.52% |
| Q32 Bio Inc. | 233.12 Million USD | -36.063% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -3398.798% |
| Alumis Inc. Common Stock | 53.5 Million USD | -492.877% |
| Equillium, Inc. | 27.95 Million USD | -1034.603% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -53.54% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -5537.46% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -5072.064% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -101.62% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -356.845% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -3080.215% |
| Dominari Holdings Inc. | 4.63 Million USD | -6743.603% |
| Edesa Biotech, Inc. | 1.84 Million USD | -17123.861% |
| vTv Therapeutics Inc. | 29.56 Million USD | -972.821% |
| Bio-Techne Corporation | 744.34 Million USD | 57.385% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -151.549% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 7.912% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -681.765% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -995.421% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -243.44% |
| Nkarta, Inc. | 105.6 Million USD | -200.38% |
| BioCardia, Inc. | 4.59 Million USD | -6810.697% |
| Iterum Therapeutics plc | 32.66 Million USD | -871.162% |